| Revenue growth | +31.9% YoY, +15.1% QoQ |
|---|---|
| Margins | EBITDA margin 14.5% vs 9.3% YoY; 15.0% in Q1 |
| Demand visibility | CDMO demand robust; deepening IPM presence |
| Management confidence | Optimistic; no numeric guidance given |
Growth
Revenue +31.9% YoY and +15.1% QoQ. EBITDA +106.1% YoY. PAT +168.3% YoY. CDMO volumes grew double digits.
Outlook
Zambia commercial supplies from Indian plant in Q4 FY27; revenue booking Q1 FY28. European CDMO project on plan. No numeric guidance.
Risks
API still EBITDA-negative (INR -6 cr). API revenue down 35.3% YoY. Trade generics revenue down 5.4% YoY.
Investor Presentation filed with BSE, NSE: AKUMS. Summary written with AI assistance from the document.
Akums Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹733.15
- Market cap
- ₹11,539 Cr
- Revenue (annual)
- ₹4,359 Cr
- Net profit (annual)
- ₹255.2 Cr
- P/E (TTM)
- 39.6×Sector 45.9×
- Promoter holding
- 75.26%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Akums Drugs & Pharmaceuticals Ltd
All →Akums Drugs & Pharmaceuticals Results Update
Akums reported Q2 FY27 revenue of ₹1,342 crore, up 31.9%, and PAT of ₹115 crore, up 168%. The release is a press update with highlights, not the full results statement.
Akums Drugs & Pharmaceuticals Q2 FY27 Results: Net Profit ₹114.6 Cr, Up 168.4% YoY
Akums Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹1,342 Cr (+31.9% YoY) and net profit of ₹114.6 Cr (+168.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹114.6 Cr · +168.4% YoY
Akums Drugs & Pharmaceuticals Management Change
Akums Drugs announced the resignation of Mr. Sunil Jaiswal, SVP R&D and Senior Management Personnel, effective 31 October 2026. The resignation was submitted on 5 August 2026 citing family commitments.
Akums Drugs & Pharmaceuticals Board Meeting Date
Akums Drugs intimated that its Board meeting is scheduled for 2 November 2026 to consider un-audited Q1 and H1 FY27 results. No financial figures or decisions have been announced yet.
Akums Drugs & Pharmaceuticals Legal & Regulatory
Akums Drugs and Pharmaceuticals received a ₹52.75 Crore NPPA demand notice. The company claims no liability, citing an indemnity agreement with its marketer.
- Value
- ₹52.75 Cr
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing notes the removal of two entities from the promoter group.